Sequenom Says Competitors Will Have to License IP for Noninvasive T21 Detection Tests
July 27, 2011
Sequenom Says Competitors Will Have to License IP for Noninvasive T21 Detection Tests
A Sequenom official said that if another company "wanted to offer a trisomy 21 [laboratory-developed test], they would need to come through us" to license the technology.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Sequenom Outlicenses Technology for T21 Test, Returns Rights of Separate Patent to TrovaGene
August 17, 2011 / Clinical Sequencing News - Sequenom Ramps up Hiring, Licenses Additional Technology as it Nears Launch of T21 Test
August 9, 2011 / Clinical Sequencing News - Building on Trisomy 21 Test, Hong Kong Team Develops Method to Detect T13 and T18
July 6, 2011 / Clinical Sequencing News - With Clinical Validation Study Complete, Sequenom Moves Ahead with 2012 Launch of T21 Test
May 10, 2011 / Clinical Sequencing News - Quake Group Issued Patent for Detection of Fetal Aneuploidy with Next-Gen Sequencing
August 31, 2011 / Clinical Sequencing News